The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments. Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments.
CTAD Clinical Trials on Alzheimer's Disease的外部链接
OO，International
CTAD Clinical Trials on Alzheimer's Disease转发了
CTAD Clinical Trials on Alzheimer's Disease 2024 was an exceptional experience. From discussing innovative trial designs to exploring the frontiers of diagnostics and treatment modalities, the conference highlighted the progress we’ve made—and the important journey ahead to improve patient outcomes. It was an honor to share our posters and engage with so many experts and collaborators for invaluable insights and inspiring discussions.
At #CTAD24, these outstanding presentations were highlighted during our Early Career Showcase Flash Sessions: ?? Flash Session 1: Association of Alzheimer’s disease biomarkers and emotional states: analysis of individuals with and without preclinical Alzheimer’s disease in the A4 trial Irina Skylar-Scott, Stanford University, Palo Alto (United States) ?? Flash Session 2: Effect of EGb761 on blood markers of inflammation and oxidative stress in a cohort of patients with Mild Cognitive Impairment (ACE-2020-EGb761) Xavier Morato Arus, PhD, Fundació ACE, Barcelona (Spain) ?? Flash Session 3: PET Imaging of Microtubules in Cognitively Normal and Impaired Older Adults: A Pilot Study Kiran K Solingapuram Sai, Wake Forest School of Medicine, Winston Salem (United States) Each of these presentations brings us closer to breakthroughs in Alzheimer’s research and therapy. Congratulations to our early career scientists for their excellent work! #AlzheimersResearch #EarlyCareerShowcase #Neuroscience #Innovation
A heartfelt thank you to everyone who joined us at #CTAD24 in Madrid! With over 2,400 attendees, this year’s Clinical Trials on Alzheimer’s Disease Congress was a testament to the dedication and drive within our community. Together, we explored the latest breakthroughs, shared invaluable insights, and strengthened our commitment to advancing Alzheimer’s research and treatment. We are deeply grateful to our speakers, sponsors, and each of you for making this event a success.The conversations and collaborations sparked here will have a lasting impact as we work towards innovative solutions in Alzheimer’s care. Thank you for being part of this journey, and we can’t wait to see where the next year takes us!
This afternoon at the Early Career Showcase D at #CTAD24, early career researchers shared pioneering studies on Alzheimer’s disease interventions and cognitive health markers. Flash Session 1: "Association Between Cognitive Performance and Emotional States: Analysis from the A4 Trial" Dr. Irina Skylar-Scott (Stanford University) examined the links between cognitive function and emotional states in Alzheimer’s patients, providing insights into potential intervention strategies. Flash Session 2: "Discrepancies in Dementia Self-Awareness: Correlations with Well-Being Across Daily Challenges" Dr. Haruaki Horie (Keio University Hospital) explored how self-awareness differences in dementia patients impact well-being, with implications for improving personalized care. Flash Session 3: "High Prevalence of Brain Amyloidopathy Among Frail Older Adults: Are They Eligible for Anti-Amyloid Treatments?" Dr. Davide Angioni (Toulouse University Hospital) presented findings on the prevalence of amyloid pathology in frail elderly, questioning current eligibility criteria for anti-amyloid treatments. Flash Session 4: "Changes in Cognitive and Neural Markers of Alzheimer’s Disease in Response to Aerobic and Non-Aerobic Exercise among Cognitively Healthy Older African Americans" Dr. Bernadette Fausto (Rutgers University) discussed the impact of exercise on Alzheimer’s biomarkers and cognitive health, highlighting non-pharmacological approaches in at-risk populations. Congratulations to these exceptional researchers advancing our understanding of Alzheimer’s disease and related conditions. #AlzheimersResearch #Biomarkers #EarlyCareerShowcase #NeurodegenerativeDiseases
This morning at the Early Career Showcase C at #CTAD24, early career researchers presented innovative studies addressing Alzheimer’s risk factors and therapeutic strategies for neurodegenerative diseases. Flash Session 1: "The Risk Factors Affecting CDR-SOB Changes in Amyloid-Beta Negative Individuals with Mild Cognitive Impairment and Subjective Memory Impairment" Dr. Hyunji Lee (Pusan National University Hospital) explored how risk factors influence cognitive decline in amyloid-beta negative individuals with mild cognitive impairment, contributing valuable insights for early risk assessment in Alzheimer’s. Flash Session 2: "Potential Role of MRI to Optimize the Design of Clinical Trials for PSP and CBD" Dr. Ignacio Illán-Gala (Hospital de la Santa Creu i Sant Pau) presented advancements in MRI methodologies for progressive supranuclear palsy and corticobasal degeneration, aiming to enhance diagnostic precision and trial design for these challenging neurodegenerative disorders. Flash Session 3: "Bumetanide in Patients with Alzheimer’s Disease (BumxAD): A Phase II Clinical Trial" Dr. Kyan Younes (Stanford University) discussed novel therapeutic strategies in targeting neuroinflammation in Alzheimer’s, representing a significant advancement in biomarker-driven clinical trials. Congratulations to these talented researchers for their contributions to the field of Alzheimer’s research. #AlzheimersResearch #Biomarkers #EarlyCareerShowcase #NeurodegenerativeDiseases
This morning at the Early Career Showcase A at #CTAD24, early career researchers shared innovative studies on Alzheimer's therapies and biomarkers. ? Flash Session 1: "Characteristics of patients attending our Alzheimer’s disease-modifying therapy clinic in Japan: Implications for clinical trials" Dr. Masanori Kurihara (Tokyo Metropolitan Institute for Geriatrics and Gerontology) discussed CSF and PET biomarkers in cognitive disorders, including Alzheimer’s, and highlighted clinical trial challenges linked to promising therapies like lecanemab. ? Flash Session 2: "Novel Trial Design for a Tau-Directed Therapeutic in Patients with Corticobasal Syndrome" Dr. Lawren VandeVrede (UCSF Memory and Aging Center) presented biomarker validation methods and a tau-targeted clinical trial for corticobasal syndrome, funded by the Part the Cloud Initiative through the Alzheimer’s Association, aiming to enhance diagnostic accuracy using plasma biomarkers. ? ?? Congratulations to these talented researchers for advancing Alzheimer’s science! #AlzheimersResearch #Biomarkers #EarlyCareerShowcase
CTAD Clinical Trials on Alzheimer's Disease转发了
SiteRx is proud to Sponsor CTAD Clinical Trials on Alzheimer's Disease 2024 and looks forward to seeing you in Madrid next week! SiteRx is a patient recruitment platform democratizing access to research at the point of care across the US. We have best-in-class expertise in Alzheimer’s disease & Neuropsychiatric symptoms related to Alzheimer's research (across Phases I-IV) with access to over 9 million patients across the SiteRx platform to match enriched longitudinal health history with protocol criteria and down-funnel support to ensure conversion of clinically pre-qualified, motivated patients to sites with health records in hand. SiteRx has experience across the AD continuum (stages I - VII) and decentralized pre-screening workflows. The SiteRx team is looking forward to meeting with you to learn more about your science.?Please schedule a meeting using the link below or reach out to VP of Life Sciences at?[email protected]. https://lnkd.in/ec7Zv9xx
Join Us in Madrid from October 29 to November 1st or Online via the #CTAD24 digital plateform ???? https://buff.ly/3Lag2ok
Check out our Late Breaking Oral Communication in the #CTAD24 Final Program now available online! ?? Check out our Late Breaking Oral Communication in the #CTAD24 Final Program now available online! ?? https://lnkd.in/d9PNfgbx
Check out the #CTAD24 list for Late Breaking Posters on our website ! ?? https://lnkd.in/e7sHa7Tj